Details of Bacterial Vaccine
This bacterial vaccine card gives comprehensive information about each vaccine.
| Detailed Information | |
|---|---|
| ID | 1343 |
| Name of the vaccine | V114 |
| Microbe | Bacteria |
| Disease name | Pneumococcal |
| Name of bacteria | Streptococcus pneumoniae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 18 to 49 years |
| Description of the vaccine | Merck’s investigational 15-valent pneumococcal conjugate vaccine. |
| Name of the manufacturer | Merck Sharp & Dohme Corp. |
| Name of the manufacturing country | Australia, Canada, Chile, New Zealand, Poland, Russian Federation, United States |
| Year of manufacture | 2020 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Single dose of 0.5 mL. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | Aluminium Phosphate |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT03547167 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA |